Skip to main content
. 2017 Oct 4;43(6):1201–1211. doi: 10.1038/npp.2017.180

Figure 2.

Figure 2

Relationships between [18F]FMT Ki and [11C]raclopride BPND for striatal regions of interest. (a) Baseline [11C]raclopride BPND following placebo was positively related to [18F]FMT Ki the whole striatum region of interest (ROI) derived from voxel-wise analyses (r=0.46, p=0.003). Baseline [11C]raclopride BPND and [18F]FMT Ki were positively related for manually drawn ROIs in dorsal caudate (r=0.34, p=0.03) and ventral striatum (r=0.41, p=0.008), and related in dorsal putamen at trend level (r=0.26, p=0.10). (b) [11C]raclopride BPND following methylphenidate and placebo (baseline) were highly correlated (r=0.72–0.90, all p<0.0001). (c) Dopamine release (([11C]raclopride placebo-[11C]raclopride methylphenidate)/ [11C]raclopride placebo) was not related to [18F]FMT Ki (r=−0.15–0.11, all p>0.35). [11C]raclopride is abbreviated as RAC.